Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
Cellular survival: a play in three Akts
Datta, S. R., Brunet, A., & Greenberg, M. E. (1999) · Genes & Development · doi:10.1101/gad.13.22.2905 · Cited by 4,216
Steck, P. A., Pershouse, M. A., Jasser, S. A., Yung, W. K. A., Lin, H., Ligon, A. H., Langford, L. A., Baumgard, M. L., Hattier, T., Davis, T., et al. (1997) · Nature Genetics · doi:10.1038/ng0497-356 · Cited by 2,741
TOR, a Central Controller of Cell Growth
Schmelzle, T., & Hall, M. N. (2000) · Cell · doi:10.1016/s0092-8674(00)00117-3 · Cited by 1,924
Johnstone (2002) · doi:10.1016/s0092-8674(02)00625-6 · Cited by 1,876
The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice
Adams, J. M., Harris, A. W., Pinkert, C. A., Corcoran, L. M., Alexander, W. S., Cory, S., Palmiter, R. D., & Brinster, R. L. (1985) · Nature · doi:10.1038/318533a0 · Cited by 1,779
Translational control of gene expression
Sonenberg, N., Hershey, J. W. B., & Mathews, M. B. (2000) · Cold Spring Harbor Laboratory eBooks · Cited by 1,379
Translational control of gene expression
Hannig, E. M. (2001) · BioEssays · doi:10.1002/bies.1108 · Cited by 1,189
Role of Translocation in the Activation and Function of Protein Kinase B
Andjelkovic, M., Alessi, D. R., Meier, R., Fernandez, A., Lamb, N. J. C., Frech, M., Cron, P., Cohen, P., Lucocq, J. M., & Hemmings, B. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.50.31515 · Cited by 1,051
Cited by
Items 101–124 of 124
Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells
Boice, M., Salloum, D., Mourcin, F., Sanghvi, V., Amin, R., Oricchio, E., Jiang, M., Mottok, A., Denis-Lagache, N., Ciriello, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.032 · Cited by 257
Self-citationFunction of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer
Chin, Y. R., & Toker, A. (2009) · Cellular Signalling · doi:10.1016/j.cellsig.2008.11.015 · Cited by 255
Translational control of tumor immune escape via the eIF4F–STAT1–PD-L1 axis in melanoma
Cerezo, M., Guemiri, R., Druillennec, S., Girault, I., Malka-Mahieu, H., Shen, S., Allard, D., Martineau, S., Welsch, C., Agoussi, S., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0217-1 · Cited by 254
Jastrzebski, K., Hannan, K. M., Tchoubrieva, E. B., Hannan, R. D., & Pearson, R. B. (2007) · Growth Factors · doi:10.1080/08977190701779101 · Cited by 240
“More recently, it has been reported that in the Em-myc model of lymphomagenesis, eIF4E is the downstream target of mTOR responsible for mediating the tumourigenic effects induced by the overexpression of AKT (Wendel et al. 2004).”
BackgroundMammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck
Amornphimoltham, P., Patel, V., Sodhi, A., Nikitakis, N. G., Sauk, J. J., Sausville, E. A., Molinolo, A. A., & Gutkind, J. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0921 · Cited by 238
“and treated with rapamycin (10 mg/kg/d) or an equal volume of diluent (22).”
Background“Translating” Tumor Hypoxia: Unfolded Protein Response (UPR)–Dependent and UPR-Independent Pathways
Koumenis, C., & Wouters, B. G. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0150 · Cited by 228
Brandts, C. H., Sargin, B., Rode, M., Biermann, C., Lindtner, B., Schwäble, J., Buerger, H., Müller-Tidow, C., Choudhary, C., McMahon, M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0422 · Cited by 212
Survival of pancreatic cancer cells lacking KRAS function
Muzumdar, M. D., Chen, P.-Y., Dorans, K. J., Chung, K. M., Bhutkar, A., Hong, E., Noll, E. M., Sprick, M. R., Trumpp, A., & Jacks, T. (2017) · Nature Communications · doi:10.1038/s41467-017-00942-5 · Cited by 177
c-Myc and eIF4F Are Components of a Feedforward Loop that Links Transcription and Translation
Lin, C.-J., Cencic, R., Mills, J. R., Robert, F., & Pelletier, J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5876 · Cited by 180
Self-citationAdvances in imaging mouse tumour models in vivo
Lyons, S. K. (2005) · The Journal of Pathology · doi:10.1002/path.1697 · Cited by 174
mTOR signaling: implications for cancer and anticancer therapy
Petroulakis, E., Mamane, Y., Le Bacquer, O., Shahbazian, D., & Sonenberg, N. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602902 · Cited by 170
Krizhanovsky, V., Xue, W., Zender, L., Yon, M., Hernando, E., & Lowe, S. W. (2008) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2008.73.048 · Cited by 138
Self-citationSchatz, J. H., Oricchio, E., Wolfe, A. L., Jiang, M., Linkov, I., Maragulia, J., Shi, W., Zhang, Z., Rajasekhar, V. K., Pagano, N. C., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110846 · Cited by 119
“2 A; Verbeek et al., 1991; Wendel et al., 2004).”
BackgroundMethodResultInfluentialSelf-citationMolecular Pathways: The eIF4F Translation Initiation Complex—New Opportunities for Cancer Treatment
Malka-Mahieu, H., Newman, M., Désaubry, L., Robert, C., & Vagner, S. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2362 · Cited by 105
“Lymphoma cells overexpressing the cap-binding protein are highly resistant to the DNA-damaging agent doxorubicin compared with controls (11), and this observation has since been extended to other types of therapies.”
BackgroundMet acts on Mdm2 via mTOR to signal cell survival during development
Moumen, A., Patané, S., Porras, A., Dono, R., & Maina, F. (2007) · Development · doi:10.1242/dev.02820 · Cited by 95
Altering chemosensitivity by modulating translation elongation
Robert, F., Carrier, M., Rawe, S., Chen, S., Lowe, S., & Pelletier, J. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005428 · Cited by 90
Self-citationPhosphorylation of MDMX Mediated by Akt Leads to Stabilization and Induces 14-3-3 Binding
Lopez-Pajares, V., Kim, M. M., & Yuan, Z.-M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m710030200 · Cited by 79
Amidino-Rocaglates: A Potent Class of eIF4A Inhibitors
Chu, J., Zhang, W., Cencic, R., Devine, W. G., Beglov, D., Henkel, T., Brown, L. E., Vajda, S., Porco, J. A., & Pelletier, J. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.08.008 · Cited by 74
“Dysregulation of mTOR signaling (through inactivation of Pten or sustained Akt activity) in this model accelerates tumor onset, suppresses apoptosis, and confers resistance towards conventional chemotherapies such as cyclophosphamide and doxorubicin (Wendel et al., 2004).”
Self-citationSHIP2 and its involvement in various diseases
Suwa, A., Kurama, T., & Shimokawa, T. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2010.492780 · Cited by 74
Wall, M., Poortinga, G., Stanley, K. L., Lindemann, R. K., Bots, M., Chan, C. J., Bywater, M. J., Kinross, K. M., Astle, M. V., Waldeck, K., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0404 · Cited by 64
Self-citationTranslation initiation factor eIF4F modifies the dexamethasone response in multiple myeloma
Robert, F., Roman, W., Bramoullé, A., Fellmann, C., Roulston, A., Shustik, C., Porco, J. A., Shore, G. C., Sebag, M., & Pelletier, J. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1402650111 · Cited by 64
Self-citationMA, J., HAN, L. Z., LIANG, H., MI, C., SHI, H., LEE, J. J., & JIN, X. (2014) · Oncology Reports · doi:10.3892/or.2014.3211 · Cited by 43
Sénéchal, P., Robert, F., Cencic, R., Yanagiya, A., Chu, J., Sonenberg, N., Paquet, M., & Pelletier, J. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03940-5 · Cited by 20
Self-citationMittenbühler, M. J., Sprenger, H.-G., Gruber, S., Wunderlich, C. M., Kern, L., Brüning, J. C., & Wunderlich, F. T. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.08.010 · Cited by 18
Metadata
- Authors
- Wendel, H.-G., Stanchina, E. D., Fridman, J. S., Malina, A., Ray, S., Kogan, S., Cordon-Cardo, C., Pelletier, J., & Lowe, S. W.
- Venue
- Nature
- Published
- 2004-03
- Volume
- 428
- Issue
- 6980
- Pages
- 332-337
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2065825082
- Cited by
- 951
- References
- 32
- FWCI
- 29.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.